|
de Leon, J H; Vatsis, K P; Weber, W W (2000) Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 58:288-99
|
|
Dhaini, H R; Levy, G N (2000) Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Pharmacogenetics 10:79-83
|
|
Estrada, L; Kanelakis, K C; Levy, G N et al. (2000) Tissue- and gender-specific expression of N-acetyltransferase 2 (Nat2*) during development of the outbred mouse strain CD-1. Drug Metab Dispos 28:139-46
|
|
Weber, W W (1999) Populations and genetic polymorphisms. Mol Diagn 4:299-307
|
|
Liu, Y; Levy, G N (1998) Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2. Cancer Lett 133:115-23
|
|
Estrada-Rodgers, L; Levy, G N; Weber, W W (1998) Characterization of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter. Gene Expr 7:13-24
|
|
Estrada-Rodgers, L; Levy, G N; Weber, W W (1998) Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells. Drug Metab Dispos 26:502-5
|
|
Liu, Y; Levy, G N; Weber, W W (1997) Induction of human prostaglandin endoperoxide H synthase-2 (PHS-2) mRNA by TCDD. Prostaglandins 53:1-10
|
|
Levy, G N (1997) Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11:234-47
|
|
Levy, G N; Rodgers, L; Weber, W W (1996) Effects of heredity on response to drugs and environmental chemicals: construction of rodent models. Chem Res Toxicol 9:1215-24
|
Showing the most recent 10 out of 27 publications
